Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Emles Venture Partners LLC, founded in 2019 by serial entrepreneur Gabriel Hammond, is a New York-based venture capital firm that specializes in seed-stage investments. The firm operates with a commitment to providing strategic and operational support to founders, emphasizing quick feedback on investment decisions and a dedication to future funding rounds. Emles aims to be the investor that founders want, offering unique debt offerings and bridge capital to help startups thrive.
Since its inception, Emles has built a diverse portfolio of 72 companies across various sectors, including AI, biotech, healthcare, food-agtech, climate, fintech, SaaS, and industrial. The firm is particularly focused on supporting female, diverse, and international founders, with 45% of its portfolio comprising female and diverse founders and 55% international founders. Emles Venture Partners is headquartered at 101 Greenwich St., Suite 8C, New York, NY 10006.
Emles Venture Partners invests primarily in seed-stage companies across a wide range of sectors, including AI, biotech, healthcare, food-agtech, climate, fintech, SaaS, and industrial. The firm does not impose traditional geographic constraints, allowing them to support startups from various locations, particularly in North America. Emles is committed to investing in underrepresented founders, with a notable emphasis on female and diverse entrepreneurs. Their portfolio reflects this commitment, showcasing 45% female and diverse founders and 55% international founders.
The firm offers bridge capital and unique debt offerings, which are designed to provide additional financial support to startups as they grow. Emles emphasizes quick decision-making in their investment process, ensuring that founders receive timely feedback and support. This approach is complemented by a commitment to follow-on funding, which helps ensure that portfolio companies have the resources they need to succeed in subsequent rounds.
Emles Venture Partners has a diverse portfolio of 72 companies, showcasing their commitment to various sectors and innovative solutions. Notable portfolio companies include:
This portfolio reflects Emles' sector-agnostic approach while emphasizing their commitment to supporting diverse and innovative founders.
Gabriel Hammond - Founder, CEO. Gabriel is a serial entrepreneur with a background in financial services. He previously founded Alerian and SteelPath, asset management firms that peaked at approximately $33 billion in assets under management. His experience in building and exiting successful businesses informs his approach at Emles Venture Partners.
Emanuel Zareh - Partner. Emanuel brings extensive experience in venture capital and operational support, contributing to the firm's commitment to helping founders succeed.
Dave Saxena - Partner. Dave has a strong background in technology and investment, enhancing Emles' ability to identify and support innovative startups.
To pitch Emles Venture Partners, founders should send their pitch decks to founder@emles.com. The pitch deck should include essential information such as the business model, market opportunity, competitive landscape, and team background. Emles values quick feedback, so founders can expect a timely response regarding their pitch.
While there is no formal application portal, a well-structured email with a clear and concise pitch deck is recommended. Founders should aim to highlight their unique value proposition and how their startup aligns with Emles' focus on diversity and innovation.
On December 19, 2023, Emles Venture Partners made a notable investment in Mytos, a biotech company focused on innovative healthcare solutions. This investment reflects the firm's ongoing commitment to supporting seed-stage companies across various sectors.
Prior to this, Emles participated in the Series A funding round for Canix in June 2022, which develops ERP software for cannabis companies. The firm has been actively investing in diverse sectors, showcasing its commitment to innovation and support for underrepresented founders.
What are Emles Venture Partners' investment criteria?
Emles focuses on seed-stage investments across various sectors, including AI, biotech, healthcare, food-agtech, climate, fintech, SaaS, and industrial. They prioritize supporting female, diverse, and international founders, with a portfolio that includes 45% female and diverse founders and 55% international founders.
How can I apply or pitch to Emles Venture Partners?
Founders can pitch to Emles Venture Partners by sending an email to founder@emles.com. It is recommended to include a detailed pitch deck that outlines the business model, market opportunity, and team background.
What makes Emles Venture Partners different from other investors?
Emles distinguishes itself through its commitment to diversity and operational support. The firm emphasizes quick feedback on investment decisions and a commitment to follow-on funding, ensuring that portfolio companies receive the necessary resources to grow.
What is the geographic scope of Emles Venture Partners?
While Emles is based in New York and primarily focuses on North America, they do not impose traditional geographic constraints, allowing them to invest in startups from various locations.
What is the typical check size for investments?
While specific check sizes are not publicly disclosed, Emles typically invests in the range of $250K to $2M for seed-stage companies.
What kind of post-investment involvement can founders expect?
Emles Venture Partners provides strategic and operational support to its portfolio companies, leveraging the experience of its team of successful founders and operators. This includes quick feedback on investment decisions and a commitment to follow-on funding.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.